Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Recruiting
Observational Study
Cholangiocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically or radiologically confirmed intrahepatic cholangiocarcinoma
* Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors
Exclusion Criteria:
* Direct surgery after hospitalization
* Initial treatment combined with local therapies (rad…
Contacts